- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02379624
Pectin Start Early Enteral Nutritional Support in Critically Ill Patients
Acute lower gastrointestinal dysfunction is a kind of much common complication which occurred in critically ill patients. Once it developed, enteral nutrition would be disturbed. In this study, investigators suppose that early application of a sufficient amount of pectin ahead of enteral nutrition, may promote recovery of acute lower gastrointestinal dysfunction in critically ill patients, and exert its good effect on early EN support.
Investigators designed this prospective randomized controlled trial to test and evaluates the effect whether EN feeding with or without a pectin start would be safe or with advanced clinical outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastrointestinal function (GI) is an important determinant in the outcome of critically ill patients, with up to 62% of patients exhibiting at least one GI symptom for at least 1 day. Unlike the upper gastrointestinal dysfunction, which can be diagnosed early because of abdominal distension, nausea, and feeding intolerance, acute lower gastrointestinal dysfunction (ALGID) is a kind of more common complication which more easily neglected due to atypical symptoms. Once ALGID developed, critical patients could not get enteral nutrition (EN) normally, as early EN support is often essential and standard on critically ill patients when feasible. It also causes colonic bacteria reflux to the ileum and jejunum, leads to ischemic necrosis or colon perforation, and increases the incidence of various adverse events.
Dietary fiber (DF) plays an important and helpful role in GI. It undergoes partial or total fermentation in the distal small bowel and colon, leading to the production of short chain fatty acids (SCFA) and gas. It also helps to conduct slower and delayed gastroenterology absorption, and reduce luminal flow. To date, many research and evidences exist for DF-supplemented EN reduces the incidence of colonic dysfunction in non-intensive care unit studies. However, until recently, it still lacks guidelines on how to conduct DF-supplemented EN rationally in critically ill patients.
Pectin, a representative DF, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying. Studies showed that 90% of ingested pectin can be found in the terminal ileum. In view of all the former studies data and on the basis of investigators' clinical observation, investigators postulate that early application of a sufficient amount of pectin ahead of EN, may promote ALGID recovery in critically ill patients, and exert its effect.
Investigators designed this prospective randomized controlled trial to test whether EN feeding with or without a pectin start would be safe or with advanced clinical outcomes. Investigators speculated that pectin start EN could nourish the digestive tract in critically ill patients, and it is superior to traditional EN feeding for the delivery of early nutritional support.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria::
- Adult ICU patients who were at least 18 years old if they were expected to require EN support within 36 hours after an unplanned ICU admission.
Exclusion Criteria:
- Could not be fed through enteral route,
- Had received EN in the past 2 months,
- Had a colectomy or jejunostomy in situ,
- Had severe colonic disease such as ulcerative colitis and Crohn's,
- Had pregnant,
- Had EN taboo crowd.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: EN group
5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h.
Since day 7, EN was began to advance to goal energy target as quickly as possibl
|
|
Experimental: PEC/EN group
An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday).
Since day 7, EN was advanced to goal energy target as the same step
|
Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages.
As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids.
It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
all-cause mortality
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
duration of organ support
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of treated infectious and noninfectious complications
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Vomiting
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Diarrhea
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Abdominal distention or Cramping
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Constipation
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Regurgitation
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Given antidiarrheal
Time Frame: 30 days
|
30 days
|
Efficacy as measured by frequency of Given prokinetic agents
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NNSF81270884
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Yale UniversityNational Institute on Aging (NIA)RecruitingCritical Illness | Illness, CriticalUnited States
-
McMaster UniversityLondon Health Sciences Centre; McMaster Children's Hospital; Canadian Critical...CompletedPediatric Critical IllnessCanada
-
Boston Children's HospitalCompleted
-
St Helens & Knowsley Teaching Hospitals NHS TrustManchester University NHS Foundation TrustCompleted
-
Sándor BeniczkyUniversity of Aarhus; Danish Council for Independent Research; Søster og Verner...CompletedCritical Illness Myopathy | Myopathy Critical IllnessDenmark
-
Hospital de Clinicas de Porto AlegreUnknownCritical Illness PolyneuropathiesBrazil
-
Peking Union Medical College HospitalBaxter Healthcare CorporationUnknownNutrition Therapy for Critical Illness
-
University Hospital Birmingham NHS Foundation TrustCompletedRehabilitation After Critical Illness
-
Assistance Publique - Hôpitaux de ParisRecruitingCritical Illness Related Corticosteroids InsufficiencyFrance
Clinical Trials on pectin
-
Nanjing PLA General HospitalCompletedIrritable Bowel Syndrome
-
Wageningen UniversityCompleted
-
Maastricht University Medical CenterCompleted
-
Jinling Hospital, ChinaCompleted
-
Lamis KaddamUnknownPolycystic Ovary SyndromeSudan
-
Jinling Hospital, ChinaTerminated
-
Massachusetts General HospitalUnknown
-
Wageningen UniversityCompleted
-
University of ManitobaRecruitingInflammatory Bowel Diseases | Ulcerative ColitisCanada
-
Jinling Hospital, ChinaUnknownInflammatory Bowel DiseaseChina